

# **SUPPLEMENTARY PROSPECTUS**

## **OPTISCAN IMAGING LIMITED [ABN 81 077 771 987]**

### **IMPORTANT NOTICE**

This Supplementary Prospectus is dated 29 July 2016 and was lodged with the Australian Securities and Investments Commission on that date. This Supplementary Prospectus supplements the Prospectus dated 22 July 2016 (**Prospectus**) issued by Optiscan Imaging Limited (**the Company**) which was lodged with the Australian Securities and Investments Commission on that date.

This Supplementary Prospectus must be read in conjunction with the Prospectus. The Australian Securities and Investments Commission and ASX Limited take no responsibility for the contents of this Supplementary Prospectus or the Prospectus.

Terms used in this Supplementary Prospectus have the same meaning as in the Prospectus unless otherwise defined or the contrary intention appears.

### **CLARIFICATION OF UNDERWRITING AGREEMENT SUMMARY – TERMINATION EVENTS**

Paragraphs 10(b) and 10(q)(xxiii) in the summary of the terms of the Underwriting Agreement in Section 10 on pages 21 and 23 of the Prospectus refer to the Company's shares finishing trading on ASX on any five (5) consecutive trading days with a closing price that is \$0.025 (2.5 cents) or less and the Company being removed from the Official List or its shares becoming suspended from Official Quotation and that suspension is being lifted within 15 Business Days following such suspension.

As set out in Section 1.6 of the Prospectus, the Company's shares are presently suspended from quotation (trading) on ASX. Paragraphs 10(b) and 10(q)(xxiii) in the summary of the terms of the Underwriting Agreement do not apply to the current suspension or the last share price before the current suspension commenced in February this year. They could only apply in respect of closing prices or a further suspension if the present suspension were to be lifted before the underwritten shares are issued. It is not expected that the suspension would be lifted before the offer closes and all offered shares including the underwritten shares are issued.

### **AMENDMENT OF DATES**

As announced on 26 July 2016, as requested by ASX the date for notification of under-subscriptions to ASX in the prospectus has been changed from 18 to 17 August 2016, and the Issue Date for shares has been changed from 22 to 19 August 2016. The dates in the timetable on page 2 and the date holding statements are anticipated to be sent in the summary table on page 6 of the Prospectus are amended accordingly. The Closing Date of the Offer remains 12 August 2016. All dates are indicative only and may change without notice.

### **CONSENTS**

The Underwriter, Life Sciences Pty Ltd has given and, as at the date hereof not withdrawn, its written consent to be named as the Underwriter of the Rights Issue in the form and context in which it is named in this supplementary prospectus. Life Sciences Pty Ltd has had no involvement in the preparation of any part of this supplementary prospectus other than being named as the Underwriter and providing confirmation regarding the underwriting summary termination events. Life Sciences Pty Ltd has not authorised or caused the issue of any part of this supplementary prospectus and, to the extent permitted by law, expressly disclaims and takes no responsibility for any part of this supplementary prospectus.

Each of the Directors of Optiscan Imaging Limited has consented to the lodgement of this Supplementary Prospectus with the Australian Securities and Investments Commission.

Signed for and on behalf of Optiscan Imaging Limited



Alan Hoffman, Non-Executive Chairman

Date: 29 July 2016

This supplementary prospectus is intended to be read in conjunction with the Company's Prospectus dated 22 July 2016.